title: Liver transplantation for hepatoblastoma.
abstract: From October 1993 to February 2007, 25 liver transplantations were performed for hepatoblastoma. Of these 25, 18 children received cadaveric grafts, and 7 received left lateral segments from living donors. Fifteen patients were at level IV in the pretreatment extent of disease staging system for hepatoblastoma (PRETEXT IV; 11 received cadaveric grafts and 4 underwent living related liver transplantation [LRLT]) and 10 were level III (PRETEXT III; 7 received cadaveric grafts and 3 underwent LRLT). Preoperative chemotherapy was given according to the risk stratification system for children with hepatoblastoma protocols of the International Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL): SIOPEL I in the first 3 patients, SIOPEL II in 6, SIOPEL III in 10, and SIOPEL IV in 3 patients. Patient and graft survival after cadaveric transplantation was 91%, 77.6%, and 77.6%, at 1, 5, and 10 years, respectively, with no retransplantations. Patient and graft survival for children undergoing LRLT was 100%, 83.3%, and 83.3%, at 1, 5, and 10 years, respectively. All surviving children but 1 remain disease-free, with a median follow up of 6.8 years (range, 0.9-14.9). There were 5 deaths at a median of 13 months post-transplantation, secondary to tumor recurrence (4) and respiratory failure (1). Liver transplantation is an established treatment for unresectable hepatoblastoma confined to the liver following chemotherapy. LRLT is a therapeutic option given that the outcome is similar to that of resection and cadaveric transplantation.
authors.affiliation: Institute of Liver Studies, King's College Hospital, School of Medicine, King's College London, London, UK.
authors.forename: Walid
authors.initials: W
authors.lastname: Faraj
authors.forename: Faisal
authors.initials: F
authors.lastname: Dar
authors.forename: Gabriele
authors.initials: G
authors.lastname: Marangoni
authors.forename: Adam
authors.initials: A
authors.lastname: Bartlett
authors.forename: Hector Vilca
authors.initials: HV
authors.lastname: Melendez
authors.forename: Dino
authors.initials: D
authors.lastname: Hadzic
authors.forename: Anil
authors.initials: A
authors.lastname: Dhawan
authors.forename: Georgina
authors.initials: G
authors.lastname: Mieli-Vergani
authors.forename: Mohamed
authors.initials: M
authors.lastname: Rela
authors.forename: Nigel
authors.initials: N
authors.lastname: Heaton
mesh_terms: D000293:Adolescent; D002102:Cadaver; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D018197:Hepatoblastoma / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007223:Infant; D008113:Liver Neoplasms / Q000601:surgery / Q000628:therapy*; D016031:Liver Transplantation / Q000379:methods*; D019520:Living Donors; D008297:Male; D012008:Recurrence; D016896:Treatment Outcome